Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

The insulin receptor INSR H1085H C>T and insulin receptor substrate 1 (IRS1) G972R polymorphisms and prostate cancer risk : a pilot study (CROSBI ID 172361)

Prilog u časopisu | izvorni znanstveni rad | međunarodna recenzija

Saračević, Andrea ; Nikolac, Nora ; Reljić, Ante ; Šimundić, Ana-Maria The insulin receptor INSR H1085H C>T and insulin receptor substrate 1 (IRS1) G972R polymorphisms and prostate cancer risk : a pilot study // Genetic Testing and Molecular Biomarkers, 15 (2011), 3; 127-131. doi: 10.1089/gtmb.2010.0112

Podaci o odgovornosti

Saračević, Andrea ; Nikolac, Nora ; Reljić, Ante ; Šimundić, Ana-Maria

engleski

The insulin receptor INSR H1085H C>T and insulin receptor substrate 1 (IRS1) G972R polymorphisms and prostate cancer risk : a pilot study

In recent years, numerous studies have focused their attention on genes that are part of the insulin/ insulin-like growth factor 1 signaling pathway, such as the insulin receptor (INSR) and the insulin receptor substrate 1 (IRS1) genes. We aimed to examine the association of INSR H1085H C>T and IRS1 G972R polymorphisms with prostate cancer (PC). We also aimed to examine possible association with cancer severity assessed by Gleason score. We have studied 180 consecutive patients referred for PC screening. The genotyping of two polymorphisms (INSR H1085H C>T and IRS1 G972R) was performed by the polymerase chain reaction–restriction fragment length polymorphism method. There was no difference in genotype ( p=0.794) or allelic ( p=0.621) frequency of the IRS1 G972R polymorphism between PC (n=119) and control (n=61) groups. However, a significant difference was found in INSR H1085H C>T polymorphism genotype and allelic distribution. Carriers of the polymorphic allele (C/T+T/T) were more frequent in control group patients than in the PC group (54.10% vs. 37.82% ; p=0.040 ; odds ratio [95% confidence interval]=0.52 [0.28–0.96]). The IRS1 and INSR polymorphism distribution did not differ in subgroups according to Gleason score. INSR H1085H C>T polymorphism seems to be associated with PC risk, whereas IRS1 G972R is not. However, because of the limited power of this study, there is a possibility that some modest effects of the IRS1 G972R polymorphism on PC risk went undetected. Neither polymorphism is associated with the degree of PC malignancy.

prostatic neoplasms; genetic polymorphism; receptor; insulin; insulin receptor substrate proteins

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o izdanju

15 (3)

2011.

127-131

objavljeno

1945-0265

10.1089/gtmb.2010.0112

Povezanost rada

Kliničke medicinske znanosti

Poveznice
Indeksiranost